Prostatic adenocarcinoma

Prostatic adenocarcinoma 

Updated: 01/29/2021

© Jun Wang, MD, PhD


General features
  • Predominantly acinar type, less commonly ductal type
  • Most common non cutaneous cancer in men in the United States
  • Predominantly > 50
  • More common in North America, Australia and northern and central Europe
Risk Factors
  • Genetic factors
Ashkenazi Jewish ancestry
BRCA1, BRCA2, Lynch syndrome
CHEK, ATM, HOXB13, etc
  • Environmental factors
High animal fat diet
Cigarette smoking
Obesity, etc
  • Hormones and growth factors
Androgen
Insulin and insulin-like growth factor
  • Protective factors
Lycopenes
Coffee
Soy products
Vitamin D, etc
 
Pathogenesis
  • Hormones, especially androgens and androgen receptor signaling
Amplification/overexpression: Most common
Mutation: Commonly in castrate-resistant cancers, most are gain-of-function mutation
Splice variants: Active AR splice variants (SVs), created by gene splicing or genomic rearrangement
Posttranslational modifications: Phosphorylation, methylation, etc
Intratumoral androgen synthesis

Clinical features
  • Asymptomatic or nonspecific presentations
  • Urinary complaints or retention, back pain, hematuria, etc
  • Symptoms associated with metastasis
Screening approaches
  • Serum prostate specific antigen (PSA)
  • Digital rectal exam
  • Biopsy if abnormal PSA, or rectal exam
Pathological findings
Marker
  • Positive: Racemase, PSA
  • Absence of basal layer: NO reactivity to p63 and 34betaE12
Management
  • Localized tumor
Radical prostatectomy
Radiation therapy
Androgen deprevation therapy
Active surveillance
  • Metastatic cancer:
Rarely curable with current technology
Therapy focus on symptom relief and slow disease progression
  • Prognostic factors: Staging, Gleason grade, tumor volume, capsular status, etc



Back to pathology of male reproductive system
Back to contents

Comments

Popular posts from this blog

Contents

Female genital tract

Neoplasms of respiratory tract